



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/256949/2012

European Medicines Agency decision P/0075/2012

of 25 April 2012

on the acceptance of a modification of an agreed paediatric investigation plan for artemether / lumefantrine (Riamet), (EMA-000777-PIP01-09-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0075/2012

of 25 April 2012

on the acceptance of a modification of an agreed paediatric investigation plan for artemether / lumefantrine (Riamet), (EMA-000777-PIP01-09-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/177/2010 issued on 21 September 2010, and decision P/205/2011 issued on 26 August 2011,

Having regard to the application submitted by Novartis Europharm Limited on 15 December 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 March 2012, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for artemether / lumefantrine (Riamet), tablet, dispersible tablet, film coated tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road Horsham, RH12 5AB, West Sussex, United Kingdom.

Done at London, 25 April 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/25032/2012

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000777-PIP01-09-M02

Scope of the application

Active substance(s):

Artemether / lumefantrine

Invented name:

Riamet

Condition(s):

Treatment of Plasmodium falciparum malaria

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Tablet

Dispersible tablet

Film coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Limited

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted to the European Medicines Agency on 15 December 2011 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/177/2010 issued on 21 September 2010, and decision P/205/2011 issued on 26 August 2011.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 12 January 2012.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 9 March 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of *Plasmodium falciparum* malaria

The waiver applies to:

- Paediatric population below 5 kg bodyweight;
- for artemether / lumefantrine tablet, oral use;
- on the grounds that the specific medicinal product in this pharmaceutical form is likely to be unsafe;
- Paediatric population from 5 kg bodyweight and above;
- for artemether / lumefantrine tablet, oral use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit as the needs are already covered.

The waiver applies to:

- Children and adolescents weighing 35 kg or more;
- for artemether / lumefantrine dispersible tablet, oral use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of *Plasmodium falciparum* malaria

2.1.1. Indication(s) targeted by the PIP

Treatment of acute uncomplicated *Plasmodium falciparum* malaria.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 35 kg.

Pharmaceutical form(s).

Dispersible tablet (20 mg artemether / 120 mg lumefantrine).

2.1.3. Studies

Area	Number of studies	Description
Quality	Total number of quality studies 1	Study 1: development of dispersible tablet for oral use.
Non-clinical	Total number of studies 2	Study 2: Juvenile development dose-ranging finding study of oral artemether in rats. Study 3: juvenile development study in rats of artemether.
Clinical	Total number of studies 2	Study 4: Randomised, investigator-blinded, multicentre, parallel-group trial to compare the efficacy, safety and tolerability of the artemether/lumefantrine dispersible tablet versus the artemether/lumefantrine tablet administered crushed in the treatment of acute uncomplicated <i>Plasmodium falciparum</i> malaria in infants and children from 5 kg to less than 35 kg body weight. Study 5: Open-label, single arm, multicentre trial to evaluate the pharmacokinetics, efficacy and safety of artemether/lumefantrine dispersible tablet in the treatment of acute uncomplicated <i>Plasmodium falciparum</i> malaria in neonates and infants who weigh less than 5 kg.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes.
Date of completion of the paediatric investigation plan:	By December 2013.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Plasmodium falciparum malaria

Authorised indications:

Treatment of acute uncomplicated Plasmodium Falciparum malaria in adult, children and infants of 5 kg and above.

Invented Name	Strength	Pharmaceutical form	Route of administration
Riamet	20 mg/120 mg artemether /lumefantrine	Dispersible tablets	Oral use